Status:
TERMINATED
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
Brigham and Women's Hospital
Boston Children's Hospital
Conditions:
Sickle Cell Disease
Sickle Cell Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Sickle Cell Disease (SCD) is a hereditary anemia that causes the red blood cells to change their shape from a round and doughnut-like shape to a half-moon/crescent, or sickled shape. People who have S...
Detailed Description
OBJECTIVES: Primary * To determine the efficacy of vorinostat (suberoylanilide hydroxamic acid, SAHA), when administered orally, in a pulsed fashion, once-a-day for 3 consecutive days every week, in...
Eligibility Criteria
Inclusion
- Diagnosis of sickle cell disease
- Clinically significant disease defined as at least 1 painful episode per year averaged over the previous 3 years or a history of priapism, stroke, acute chest syndrome, avascular necrosis, multi-organ failure or the need for chronic narcotic medications for pain from sickle cell disease
- Must have failed a previous attempt at treatment with hydroxyurea defined as the inability to achieve a significant absolute increase in % fetal hemoglobin or the inability to tolerate hydroxyurea treatment due to severe side effects such as but not limited to myelosuppression, gastrointestinal symptoms, edema or hepatic enzyme elevations or have contraindications to hydroxyurea
- 18 years of age or older
- Hematologic laboratory values as outlined in the protocol
- Non-hematologic laboratory values as outlined in the protocol
- Must agree not to donate blood or other bodily fluid while taking the study drug and for 28 days thereafter
- Women of child-bearing potential (WCBP) must have a negative serum pregnancy test 72 hours or less prior to starting treatment
- Women of child-bearing potential and men must agree to use 2 forms of adequate contraception prior to study entry and for the duration of study participation
Exclusion
- Subjects with hemoglobin SC or SB+ thalassemia
- Subjects on chronic transfusion program
- Subjects who have received RBC transfusions cannot have \>15% adult hemoglobin
- Known positive status for HIV, active hepatitis B or hepatitis C
- Pregnant or breast feeding women
- Individuals with a history of malignancy are ineligible except for the following circumstances. Individuals with a history of malignancy are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancer are eligible if diagnosed and adequately treated within the past 5 years: cervical or breast cancer in situ, and basal cell or squamous cell carcinoma of the skin
- Subjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk
- Subjects with unresolved infections
- Severe or uncontrolled medical conditions that could compromise study participation
- Subjects on fetal hemoglobin inducing agents
- Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy
- Known allergic reaction to a histone deacetylase inhibitor
- Subjects who have received valproic acid for treatment of epilepsy within 30 days of enrollment
- Subjects who have received any HDAC inhibitors other than valproic acid
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01000155
Start Date
October 1 2009
End Date
October 1 2014
Last Update
July 21 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
2
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
3
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115